Learn about
Problem
The heparin market depends heavily on animal-derived supply chains, creating pressure on availability, consistency, and long-term resilience.
Solution
ExCulture is developing an animal-free heparin alternative from bio-based secondary feedstocks. Our process uses biowaste-derived input streams and downstream purification to work toward defined heparin-like material.
Supported by
What drives us?
To develop animal-free heparin alternatives from bio-based secondary feedstocks and contribute to a more sustainable supply of complex biopharmaceutical materials.
ExCulture secures funding from the Dutch Industrial Biotech Seed Fund (managed by Capricorn Partners) and TTT Medtech
Leiden, 12th July 2024 - ExCulture B.V., a biotechnology startup focused on the development of an animal-free heparin substitute via fermentation,...
DSM Firmenich Kickstart Fund
On Friday 12th April 2024 ExCulture was announced as winner of the 2024 DSM-Firmenich Kickstart Prize, securing €50,000 after pitching to and...
Bio Spring Conference
Looking back on a successful first experience of the BioEurope Spring Conference held in Barcelona for ExCulture.We had the opportunity to make many...